Targeted Screening for Barrett's Esophagus and Esophageal Cancer: Post Hoc Analysis From the Randomized BEST3 Trial

Gastroenterology. 2024 May 6:S0016-5085(24)00495-5. doi: 10.1053/j.gastro.2024.04.030. Online ahead of print.

BEST3 Trial Team:
Massimiliano di Pietro, Maria O'Donovan, Beth Muldrew, Irene Debiram-Beecham, Marcel Gehrung, Monika Tripathi, Samuel G Smith, Benoit Aigret, Fiona M Walter, Greg Rubin

¹ Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
² King's College London Cancer Prevention Trials Unit, Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, King's College London, Innovation Hub, Guys Cancer Centre, Guy's Hospital, Great Maze Pond, United Kingdom.
³ Centre for Cancer Screening, Prevention, and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom; School of Cancer & Pharmaceutical Sciences, King's College London, Innovation Hub, Guys Cancer Centre, Guy's Hospital, Great Maze Pond, London, United Kingdom.
⁴ King's College London Cancer Prevention Trials Unit, Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, King's College London, Innovation Hub, Guys Cancer Centre, Guy's Hospital, Great Maze Pond, United Kingdom; Centre for Cancer Screening, Prevention, and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.

No abstract available